{"contentid": 488186, "importid": NaN, "name": "Fotivda added into NCCN clinical practice guidelines", "introduction": "The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include AVEO Oncology\u00e2\u0080\u0099s Fotivda (tivozanib) as a recommended regimen for subsequent therapy.", "content": "<p>The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include AVEO Oncology&rsquo;s (Nasdaq: AVE) Fotivda (tivozanib) as a recommended regimen for subsequent therapy.</p>\n<p>This category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma.</p>\n<p>Fotivda, an oral, next-generation vascular endothelial growth factor tyrosine kinase inhibitor, was initially discovered by Kyowa Kirin (TYO: 4151). It is also being studied by the Japanese pharma group&nbsp;in wet acute macular degeneration.</p>\n<p>After several US setbacks that led to its indication being narrowed, Fotivda was approved earlier this month by the US Food and Drug Administration for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. It had received approval in Europe in 2017 for advanced RCC and is marketed there by EUSA Pharma, part of Jazz Pharmaceuticals (Nasdaq: JAZZ).</p>\n<p>Michael Bailey, president and chief executive of Boston-based AVEO, said: &ldquo;Fotivda&rsquo;s addition to the NCCN Guidelines provides further validation for its potential to serve as an important evidence-based, well-tolerated treatment option for patients with relapsed or refractory advanced RCC.&rdquo;</p>\n<p>&ldquo;As previously announced, launch efforts are now underway, and we are committed to bringing this promising therapy to as many appropriate patients as possible.&rdquo;</p>", "date": "2021-03-29 15:36:00", "meta_title": NaN, "meta_keywords": "Fotivda, NCCN, guidelines, clinical, practice, regimen, AVEO, therapy, added, Cancer, updated, include, Comprehensive, tivozanib, recommended, National", "meta_description": "The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include AVEO Oncology\u00e2\u0080\u0099s Fotivda (tivozanib) as a recommended re", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-29 15:34:38", "updated": "2021-03-29 16:26:14", "access": NaN, "url": "https://www.thepharmaletter.com/article/fotivda-added-into-nccn-clinical-practice-guidelines", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "aveo_oncology_large.jpg", "image2id": "aveo_oncology_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Nephrology and Hepatology, Oncology", "topic_tag": "Focus On, Pricing, reimbursement and access", "geography_tag": "USA", "company_tag": "AVEO Oncology", "drug_tag": "Fotivda", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-29 15:36:00"}